Jiangsu HengRui Medicine Co., Ltd.: Ovarian Neoplasms trials

The registry lists 15 Ovarian Neoplasms studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 6Phase 3 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian CancerNot yet recruitingNCT07779538Phase 3
• A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerRecruitingNCT06840002Phase 1/2
• A Study of SHR-A1811 in Subjects With Ovarian CancerRecruitingNCT06828354Phase 3
• SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerRecruitingNCT06394492Phase 3
• A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian CancerRecruitingNCT06308406Phase 1/2
• A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian CancerNot yet recruitingNCT06211023Phase 2/3
• A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian CancerCompletedNCT04718740Phase 1
• A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
• Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04383977Phase 2
• A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
• Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04000295Phase 3
• A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer PatientsCompletedNCT03863860Phase 3
• Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
• A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian CancerCompletedNCT03509636Phase 1
• A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1